Skip to main content
. Author manuscript; available in PMC: 2018 Nov 25.
Published in final edited form as: Am J Physiol Heart Circ Physiol. 2006 Oct 13;292(2):H1077–H1084. doi: 10.1152/ajpheart.00515.2006

Fig. 2.

Fig. 2.

Effects on lifespan and cardiac hypertrophy from chronic administration of MRS-2339 in CSQ mice. A: Kaplan-Meier analysis was used to determine the survival probability in CSQ animals receiving vehicle or MRS-2339 via Alzet minipump. MRS-2339 was infused as a 3-μM sterile solution at a rate of ~6 μl/day for 28 days. Log rank test method was used to analyze the survival curves (P = 0.02). B: myocyte cross-sectional areas were determined in vehicle- and MRS-2339-treated mice, as described in METHODS. Chronic treatment with MRS-2339 caused a significant decrease in the cell cross-sectional area (P < 0.05). C: MRS-2339 treatment decreased the heart weight-to-body weight ratio in CSQ mice (P < 0.05). All data were provided as means ± SD.